Evidence map›Paper›PMID 25355214›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2014

Interaction of the cell adhesion molecule CHL1 with vitronectin, integrins, and the plasminogen activator inhibitor-2 promotes CHL1-induced neurite outgrowth and neuronal migration.

Jelena Katic, Gabriele Loers, Ralf Kleene, Nicole Karl, Carsten Schmidt, Friedrich Buck, Jaroslaw W Zmijewski, Igor Jakovcevski, Klaus T Preissner, Melitta Schachner

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 52 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Jelena KaticZentrum für Molekulare Neurobiologie, and.
Gabriele LoersZentrum für Molekulare Neurobiologie, and.
Ralf KleeneZentrum für Molekulare Neurobiologie, and.
Nicole KarlZentrum für Molekulare Neurobiologie, and.
Carsten SchmidtZentrum für Molekulare Neurobiologie, and.
Friedrich BuckInstitut für Klinische Chemie, Universitätsklinikum Hamburg-Eppendorf, 20246 Hamburg, Germany.
Jaroslaw W ZmijewskiDivision of Pulmonary, Allergy & Critical Care Medicine, University of Alabama at Birmingham, BMRII-304, Birmingham, Alabama 35294.
Igor JakovcevskiZentrum für Molekulare Neurobiologie, and.
Klaus T PreissnerDepartment of Biochemistry, Medical School, Justus-Liebig-University, 35392 Giessen, Germany.
Melitta SchachnerKeck Center for Collaborative Neuroscience and Department of Cell Biology and Neuroscience, Rutgers University, Piscataway, New Jersey 08854, Center for Neuroscience, Shantou University Medical College, Shantou 515041, People's Republic of China, and schachner@biology.rutgers.edu.
Shantou University Medical College · CNUniversität Hamburg · DEUniversity of Alabama at Birmingham · USUniversity of Giessen · DE

Funding

AMPK activation and acute lung injuryR01HL107585 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ZMIJEWSKI, JAROSLAW WALDEMAR · 2012 to 2015
$1.4M
6 · The paper itself

Abstract

The cell adhesion molecule close homolog of L1 (CHL1) plays important functional roles in the developing and adult nervous system. In search of the binding partners that mediate the diverse and sometimes opposing functions of CHL1, the extracellular matrix-associated proteins vitronectin and plasminogen activator inhibitor-2 (PAI-2) were identified as novel CHL1 interaction partners and tested for involvement in CHL1-dependent functions during mouse cerebellar development. CHL1-induced cerebellar neurite outgrowth and cell migration at postnatal days 6-8 were inhibited by a CHL1-derived peptide comprising the integrin binding RGD motif, and by antibodies against vitronectin or several integrins, indicating a vitronectin-dependent integrin-mediated pathway. A PAI-2-derived peptide, or antibodies against PAI-2, urokinase type plasminogen activator (uPA), uPA receptor, and several integrins reduced cell migration. CHL1 colocalized with vitronectin, PAI-2, and several integrins in cerebellar granule cells, suggesting an association among these proteins. Interestingly, at the slightly earlier age of 4-5 d, cerebellar neurons did not depend on CHL1 for neuritogenesis and cell migration. However, differentiation of progenitor cells into neurons at this stage was dependent on homophilic CHL1-CHL1 interactions. These observations indicate that homophilic CHL1 trans-interactions regulate differentiation of neuronal progenitor cells at early postnatal stages, while heterophilic trans-interactions of CHL1 with vitronectin, integrins, and the plasminogen activator system regulate neuritogenesis and neuronal cell migration at a later postnatal stage of cerebellar morphogenesis. Thus, within very narrow time windows in postnatal cerebellar development, distinct types of molecular interactions mediated by CHL1 underlie the diverse functions of this protein.

Indexed as

AnimalsCell Adhesion MoleculesCell MovementCells, CulturedCerebellumIntegrinsMiceMice, KnockoutNeuritesNeuronsPlasminogen Activator Inhibitor 2VitronectinCell Adhesion MoleculesChl1 protein, mouseIntegrinsPlasminogen Activator Inhibitor 2Vitronectincerebellar developmentCHL1integrinsmigrationplasminogen systemvitronectin

Identifiers

PMID25355214
PMCPMC6608427
OpenAlexW1965773046

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.